Speech Processing Solutions Introduces the Philips SpeechMike Ambient — A Wearable AI Assistant to Transform Clinical Documentation
9.9.2025 14:00:00 CEST | Business Wire | Press Release
Speech Processing Solutions, global leader in professional dictation solutions under the Philips brand, today announced the launch of the Philips SpeechMike Ambient Wearable AI Assistant, a next-generation professional grade microphone designed to transform the way of working in healthcare with ambient AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909514295/en/
Communicate, document, care: the Philips SpeechMike Ambient.
The new SpeechMike Ambient addresses the growing administrative burdens, language barriers challenges and extreme time pressure faced by clinicians today. By capturing and processing speech in real time with the help of patented, AI-driven technology, and when integrated into third-party software platforms, the device brings automatic transcription, clinical note generation, multilingual interpretation, and virtual assistant functions to the next level. This powerful tool helps clinicians focus more on their patients instead of manual administration tasks, improving care quality and reducing burnout.
The SpeechMike Ambient is engineered with four high performance beam-forming microphones, patented AI speaker separation technology and selectable audio modes for different use cases, such as single user in noisy environments or doctor-patient conversations. This device delivers studio-quality, intelligible audio even in dynamic hospital environments. Its compact, lightweight, wearable design ensures comfort during long shifts, with all-day battery life and hygienic materials built for heavy duty use in clinical environment.
Key features include:
- Optimized for conversational AI and ambient scribe solutions: Purpose built to boost transcription accuracy of conversational AI solutions and integrate seamlessly with AI-powered, voice-operated platforms
- Enterprise grade security: Encrypted Bluetooth LE communication with passkey pairing and compliance with global standards (such as CE, FCC and RCM)
- Developer ready integration: A comprehensive software development kit (SDK) and API access for rapid integration and onboarding into native clinical software systems
- Full plug-and play capability: Integrates effortlessly with existing Philips SpeechMike hardware for a powerful, all-rounder solution
- Flexible wearing options for mobility and handsfree use: Magnetic clip, neck strap for mobile use and even a docking station for stationary use
“The SpeechMike Ambient is the latest generation of the undisputed globally leading Philips SpeechMike product family, building on the strengths of Philips SpeechMike while significantly expanding its use cases – especially for AI-based ambient scribe solutions,” said Dr. Thomas Brauner, CEO at Speech Processing Solutions. “By combining wearable convenience with powerful ambient AI, we are helping healthcare professionals spend less time on paperwork and more time on patient care.
Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS), the global leader in professional AI-powered dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom and the United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909514295/en/
Contacts
Press contact:
Speech Processing Solutions
Alice Elt
Content & PR Manager
Email: alice.elt@speech.com
www.philips.com/dictation -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.philips.com
%2Fdictation&esheet=54321086&newsitemid=20250909514295&lan=en-US&anchor=www.phil
ips.com%2Fdictation&index=1&md5=83f8f2ecfb8766e9ee221e500f55d120 |
www.speechlive.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.speechlive.
com%2F&esheet=54321086&newsitemid=20250909514295&lan=en-US&anchor=www.speechlive
.com&index=2&md5=19d7da56f81bc3425fef3c4928e75c89
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom